On the afternoon of February 14, Chairman Professor Shi Yuanyuan, Chief scientist Professor Wang Jianxun, Deputy General manager Tang Xiaomeng, Assistant Chairman Wei Zheng and his delegation visited the Beijing Operation Center of Heyuan Biology. Lu Lulu, founder and CEO of Heyuan Biology, Zhou Li, Chief scientist, Wang Yongzeng, Chief Technology Officer, Zhao Linhai, SVP of Operations, Zhu Yi, VP of Business development, Deng Yiping, Strategy Director and Liu Shaozhou, assistant CEO, warmly received and exchanged ideas. As a leading domestic cell therapy drug development enterprise, Heyuan Biology has obtained three IND clinical approvals in China, of which CD19 target CAR T drug CNCT19 cell injection is expected to be approved in the near future to become the first listed independent intellectual property rights targeting CD19 CAR T products.

At the symposium, Chairman Shi Yuanyuan first introduced the original intention of Cell Valley construction, development history, core team, scientific research advantages, strategic positioning and other aspects, and Lu Lulu, CEO of Heyuan Biology, introduced the development of Heyuan Biology in detail. The teams of the two sides discussed the use, production, concentration methods of domestic and foreign retroviral vectors and the relatively high market share of lentiviral vectors. Professor Wang Jianxun, chairman and chief scientist of Shi Yuan, analyzed the proportion of R&D pipelines using different types of virus vectors in the world and the development status of the domestic virus vector industry, and proposed the necessity of building an retroviral vector production line from many aspects such as the safety of retroviral vectors, virus vector titer, industrial cost advantage, and industrial layout. The team of Heyuan Biology highly agreed with the in-depth analysis of Shenzhen Cell Valley, and proposed that although the production line of Heyuan Biology lentiviral vector is mature at present, it is willing to cooperate closely with Shenzhen Cell Valley in the development of new pipelines, the establishment of new product lines and the construction of R&D and production branches in South China to develop cell drugs based on retroviral vector technology. Jointly promote the rapid development of the cell therapy industry The two teams expressed that the spirit of the meeting should be implemented as soon as possible, and new pipeline research and development should be carried out as soon as possible to lay a solid foundation for comprehensive strategic cooperation.